The Grenoble Alpes University Hospital is a French teaching hospital built in 1974. With a total capacity of over 2 133 beds in 2020, it is the main hospital of Grenoble and Isère in France.

During the past decade, CHU de Grenoble conducted 586 clinical trials. In the 10-year time frame, 586 clinical trials started and 57 clinical trials were completed, i.e. on average, 9.7% percent of trials that started reached the finish line to date. In the past 5 years, 297 clinical trials started and 48 clinical trials were completed. i.e. 16.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU de Grenoble" #1 sponsor was "University Hospital, Grenoble" with 165 trials, followed by "Centre Hospitalier Universitaire de Saint Etienne" with 39 trials sponsored, "Intergroupe Francophone de Cancerologie Thoracique" with 25 trials sponsored, "Hospices Civils de Lyon" with 24 trials sponsored and "University Hospital, Bordeaux" with 24 trials sponsored. Other sponsors include 561 different institutions and companies that sponsored additional 233 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU de Grenoble" #1 collaborator was "Ministry of Health, France" with 30 trials as a collaborator, "University Hospital, Grenoble" with 21 trials as a collaborator, "Assistance Publique - Hôpitaux de Paris" with 10 trials as a collaborator, "National Cancer Institute, France" with 10 trials as a collaborator and "Hospices Civils de Lyon" with 9 trials as a collaborator. Other collaborators include 513 different institutions and companies that were collaborators in the rest 365 trials.

According to Clinical.Site data, the most researched conditions in "CHU de Grenoble" are "Myelodysplastic Syndromes" (17 trials), "Breast Cancer" (13 trials), "Obstructive Sleep Apnea" (13 trials), "Parkinson Disease" (12 trials) and "Heart Failure" (11 trials). Many other conditions were trialed in "CHU de Grenoble" in a lesser frequency.

Most popular intervention types in "CHU de Grenoble" are "Drug" (357 trials), "Other" (193 trials), "Device" (118 trials), "Procedure" (98 trials) and "Biological" (39 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (56 trials), "radiation therapy" (13 trials), "fluorouracil" (10 trials), "Carboplatin" (8 trials) and "Gemcitabine" (8 trials). Other intervention names were less common.

The vast majority of trials in "CHU de Grenoble" are 795 trials for "All" genders, 31 trials for "Female" genders and 13 trials for "Male" genders.

Currently, there are 291 active trials in "CHU de Grenoble". 9 are not yet recruiting, 206 are recruiting, 72 are Active, not recruiting, and 4 are Enrolling by invitation. In total, there were 385 completed trials in CHU de Grenoble, 2 suspended trials, and 67 terminated clinical trials to date.

Out of the total trials that were conducted in CHU de Grenoble, 26 "Phase 1" clinical trials were conducted, 163 "Phase 2" clinical trials and 192 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 25 trials, and there were also 228 trials that are defined as “Not Applicable".

CHU de Grenoble has several departments that took part in Clinical trials: "University Hospital, Department of Endocrinology" - 5 trials, "Intensive Care Unit - Hospital Grenoble Alpes" - 2 trials